Candidiasis is a major fungal infection worldwide, with invasive forms linked to high morbidity and mortality. The emergence of azole resistance in causing candidemia led us to examine the epidemiology and antifungal susceptibility of species at the University Hospital of Liège between January 2017 and December 2023. A total of 916 isolates from blood or sterile body fluids, tissues, and abscesses were analyzed. Species identification was performed using MALDI-TOF MS and antifungal susceptibility testing via Sensititre YO10 AST was interpreted according to the CLSI guidelines. remained the predominant species (56%), followed by (19%), (8%), and (7%). No significant shift toward non- species (NAC) was observed even during the COVID-19 pandemic, supporting the use of narrow-spectrum empirical therapy in selected patients. Fluconazole susceptibility was high in (98.8%), whereas and showed high resistance rates with 10.1% and 16.9%, respectively. showed stable fluconazole susceptibility across the study period. Echinocandins demonstrated excellent activity (95.6-100%), and amphotericin B was effective against nearly all isolates. This seven-year surveillance at the University Hospital of Liège confirms that while remains the predominant and highly susceptible species, rising azole resistance in non--particularly and -highlights the critical need for ongoing local epidemiological monitoring to guide effective and targeted antifungal therapy.